Meeting dual HbA1c and LDL-C goals improves diabetes care

July 9, 2013
Meeting dual HbA1c & LDL-C goals improves diabetes care
Dual achievement of both glycated hemoglobin and low-density lipoprotein cholesterol goals among patients with diabetes is associated with greater clinical and economic benefit than achievement of either goal alone, according to a study published online June 25 in Diabetes Care.

(HealthDay)—Dual achievement of both glycated hemoglobin (HbA1c) and low-density lipoprotein cholesterol (LDL-C) goals among patients with diabetes is associated with greater clinical and economic benefit than achievement of either goal alone, according to a study published online June 25 in Diabetes Care.

Lizheng Shi, Ph.D., from Tulane University in New Orleans, and colleagues retrospectively evaluated from 75,646 adult patients with with two or more measurements of LDL-C and HbA1c from Jan. 1, 2004, to June 30, 2010. Microvascular and cardiovascular outcomes were compared by goal achievement status. Diabetes-related resource utilization was assessed via hospitalization days and number of outpatient visits and medical service costs.

The researchers found that dual-goal achievement was associated with lower risk of (adjusted hazard ratio [aHR], 0.79), acute coronary syndrome (0.88), percutaneous coronary intervention (0.78), and (CABG; 0.74), compared to achievement of only the LDL-C goal. Dual-goal achievement was also associated with fewer hospitalization days (adjusted incidence rate ratio [aIRR], 0.93) and outpatient visits (0.88), as well as lower diabetes-related annual medical costs (?$130.89). Dual-goal achievement was associated with lower risk of the composite cardiovascular-related end point (aHR, 0.87) and CABG (aHR, 0.62), and fewer outpatient visits (aIRR, 0.98), compared to achievement of only the HbA1c goal.

"Achieving both HbA1c and LDL-C goals in diabetes care is associated with additional clinical and economic benefits, as compared with the achievement of either goal alone," the authors write.

Several authors disclosed financial ties to Daiichi Sankyo, which sponsored the study.

Explore further: Fasting plasma glucose beats HbA1c for diabetes screening

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Fasting plasma glucose beats HbA1c for diabetes screening

January 17, 2013
(HealthDay)—For patients without diabetes undergoing coronary angiography (CAG), fasting plasma glucose (FPG) performs better in diabetes screening than glycated hemoglobin (HbA1c), according to a study published online ...

Diabetes target achievement up from 1999 to 2010, more needed

April 25, 2013
(HealthDay)—For U.S. adults with diabetes there has been an improvement in achievement of targets from 1999 to 2010, but many still do not meet the recommended goals, according to research published in the April 25 issue ...

Lixisenatide non-inferior to exenatide for diabetes

June 7, 2013
(HealthDay)—In adults with type 2 diabetes not adequately controlled with metformin, lixisenatide once daily offers diabetes control similar to that of exenatide twice daily, with some added benefits, according to a study ...

Most youth with type 1 diabetes don't meet HbA1c goals

February 8, 2013
(HealthDay)—Most children with type 1 diabetes (T1D) have hemoglobin A1c (HbA1c) values above target levels, according to a study published online Jan. 22 in Diabetes Care.

Gastric bypass surgery may help manage diabetes risk factors

June 4, 2013
Among mild to moderately obese patients with type 2 diabetes, adding gastric bypass surgery to lifestyle and medical management was associated with a greater likelihood of improved levels of metabolic risk factors such as ...

Sulfonylureas up cardio events versus metformin

November 7, 2012
(HealthDay)—Use of sulfonylureas for initial treatment of diabetes is associated with increased cardiovascular events and death compared with metformin, according to a study published in the Nov. 6 issue of the Annals of ...

Recommended for you

Genetic discovery may help better identify children at risk for type 1 diabetes

January 17, 2018
Six novel chromosomal regions identified by scientists leading a large, prospective study of children at risk for type 1 diabetes will enable the discovery of more genes that cause the disease and more targets for treating ...

Women who have gestational diabetes in pregnancy are at higher risk of future health issues

January 16, 2018
Women who have gestational diabetes mellitus (GDM) during pregnancy have a higher than usual risk of developing type 2 diabetes, hypertension, and ischemic heart disease in the future, according to new research led by the ...

Diabetes gene found that causes low and high blood sugar levels in the same family

January 15, 2018
A study of families with rare blood sugar conditions has revealed a new gene thought to be critical in the regulation of insulin, the key hormone in diabetes.

Discovery could lead to new therapies for diabetics

January 12, 2018
New research by MDI Biological Laboratory scientist Sandra Rieger, Ph.D., and her team has demonstrated that an enzyme she had previously identified as playing a role in peripheral neuropathy induced by cancer chemotherapy ...

Enzyme shown to regulate inflammation and metabolism in fat tissue

January 11, 2018
The human body has two primary kinds of fat—white fat, which stores excess calories and is associated with obesity, and brown fat, which burns calories in order to produce heat and has garnered interest as a potential means ...

Big strides made in diabetes care

January 5, 2018
(HealthDay)—This past year was a busy, productive one for diabetes research and care.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

gaucho25
not rated yet Jul 09, 2013
This new FDA approve diet pill has a dramatic effect on diabetes.

ADA Poster Presentation Abstract from the June Chicago convention
Lorcaserin, (Belviq) a selective 5-HT2C agonist, was recently approved for weight management in conjunction with lifestyle modification in obese patients (BMI ≥30) and overweight patients (BMI ≥27) with at least one co-morbidity. In patients without diabetes, proportions achieving ≥5% weight loss and absolute weight loss at Week (W)52 for lorcaserin vs. placebo were 47 vs. 23% and 5.8 vs. 2.5kg respectively (MITT-LOCF). In patients with type 2 diabetes mellitus (T2DM) results were 38 vs.16% and 4.7 vs.1.6kg respectively.

To limit exposure and maximize benefit the predictive value for >5% W52 weight loss was assessed at W12. Patients not losing at least 5% at W12 (non-responders) should be discontinued.

Proportions of responders without diabetes lorcaserin vs. placebo were 49.3 vs. 22.6%. W52 weight loss in lorcaserin responders without diabetes was 10.6kg (23 lbs) with 86% and 50% achieving at least 5% and 10% weight loss respectively.

Proportions of responders with T2DM lorcaserin vs. placebo were 35.9 vs. 11.5%. W52 weight loss in lorcaserin responders with T2DM was 9.3kg (20 lbs) with 71% and 36% achieving 5% and 10% weight loss. W52 reductions in FPG and A1C in lorcaserin responders with T2DM were 29.3mg/dL and 1.2%. W52 reductions in systolic and diastolic BP and heart rate were 3.4mmHg 2.5mmHg and 2.5BPM in lorcaserin responders without diabetes and 2.6mmHg 1.9mmHg and
3.2BPM in lorcaserin responders with T2DM.

Achievement of ≥5% weight loss by W12 is a strong predictor of robust one-year lorcaserin responses in weight cardiovascular vital signs and glycemia.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.